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Introduction
Phospholipases A2 (PLA2) catalyze the hydrolysis of the sn-2 ester bond of
glycerophospholipids producing free fatty acids and lysophospholipids. The free arachidonic
acid (AA) that is released may be converted to a variety of proinflammatory eicosanoids.
Therefore, inhibiting AA release is of great therapeutic relevance for the development of new
anti-inflammatory drugs. Moreover, selective inhibition of the less studied enzyme of the
three main categories, GVIA iPLA2, may offer valuable information about the enzyme’s
physiological role. A new class of PLA2 inhibitors has been developed by our group: long
chain 2-oxoamides based on amino acids.1-3 Among others, we have shown that two
molecules based on a pseudodipeptide ethyl ester and a dipeptide tert-butyl ester are the first
2-oxoamide derivatives, which preferentially inhibit GVIA iPLA2 with ΧΙ(50) values of 0.017
and 0.011 μΜ, respectively.4 To extend our studies, we synthesized a variety of 2-oxoamides
based on dipeptides and ether pseudodipeptides, bearing an aryl terminal group on their 2-
oxoamide aliphatic chain and we studied their in vitro activity on three human PLA2 classes:
GIVA cPLA2, GVIA iPLA2 and GV sPLA2.
Synthesis
As starting materials for the synthesis of 2-hydroxy-acids we used 5-phenyl-1-pentanol (1)
and 2-naphthaldehyde (4). Alcohol 1 was oxidized to aldehyde using the AcNH-TEMPO
method, which was treated with NaHSO3/KCN to provide the corresponding cyanhydrin 2.
The latter was converted to the 2-hydroxy-acid 3 after treatment with condensed hydrochloric
acid and subsequently with potassium hydroxide in a solution of ethanol/water. 2-
Naphthaldehyde (4) underwent a Horner – Wadsworth – Emmons olefination, in order to
extend the carbon chain, followed by catalytic hydrogenation. The resulting ester 6 was
reduced to the corresponding alcohol 7 using DIBALH. Following the same chemical steps as
previously, cyanhydrin 8 was obtained, which was converted to the 2-hydroxy-methylester 9
after treatment with methanolic hydrochloride. The desired 2-hydroxy-acid 10 was produced
after saponification (Scheme 1). N-Protected L-norleucines 11a,b and glycine esters 12a,b
were coupled using WSCI.HCl as a condensing agent in the presence of HOBt to provide the
desired dipeptides (13a,b) (Scheme 2), while the pseudodipeptide 20 was obtained after
reaction of L-norleucinol with tert-butyl bromoacetate under phase transfer conditions
(Scheme 3).
Scheme 1. Reagents and conditions: a) i. NaOCl, NaBr, AcNH-TEMPO, NaHCO3, AcOEt/toluene/H2O 3:3:0.5, -5
oC; ii. NaHSO3, KCN, CH2Cl2, H2O; b) i. conc. HCl, ii. KOH, EtOH/H2O; c) C2H5OOCCH=CHCH2P(=O)(OC2H5)2,
LiOH, THF, reflux; d) H2, 10% Pd/C, EtOH; e) DIBALH, anhydrous Et2O; f) 3N HCl/ MeOH; g) NaOH 1N, MeOH.
Scheme 2. Reagents and conditions: a) WSCI, HOBt, Et3N, CH2Cl2; b) H2, 10% Pd/C, THF; c) 4N HCl/Et2O; d)
Dess-Martin periodinane, CH2Cl2; e) 50% TFA/CH2Cl2.
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Coupling reaction between the free amino group of the dipeptides or the ether
pseudodipeptide and the 2-hydroxy acid took place in the presence of WSCI/HOBt and the
resulting 2-hydroxy amides 15a-d and 22a,b were oxidized to 2-oxoamides 16a-d and 23a,b
using the Dess-Martin method. Oxoamides 17a,c and 24a,b containing a free carboxyl group,
were obtained by treatment of 16a,c and 23a,b with trifluoroacetic acid (Schemes 2 and 3).
Scheme 3. Reagents and conditions: a) i. NMM, ClCOOEt, THF; ii. NaBH4, CH3OH; b) BrCH2COOBu
t, 50%
NaOH, Bu4NHSO4, benzene; c) H2, 10% Pd/C; d) WSCI, HOBt, Et3N, CH2Cl2; e) Dess-Martin periodinane, CH2Cl2;
f) 50% TFA/CH2Cl2.
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Results and discussion
Preliminary PLA2 inhibition results are summarized in Table 1. Derivatives 24 and 25 have
been also included for comparison reasons. Among the seven compounds tested, 16a and 16c,
based on Nle-Gly tert-butyl ester, bearing phenyl and naphthyl side chain terminal moieties
respectively, appear to inhibit preferentially GVIA iPLA2. This observation is in full
agreement with our previous report, that the 2-oxoamide derivative based on Nle-Gly tert-
butyl ester (24) is potent and selective inhibitor of GVIA iPLA2.
4 The other two tert-butyl
esters of this series, namely 23a and 23b, based on ether pseudodipeptides, exhibited
considerable but lower activity towards GVIA iPLA2, though they inhibit also GIVA cPLA2 to
a similar level. 2-Oxoamide derivatives containing free carboxylic acids (17a and 17c) do not
inhibit GVIA iPLA2.
Compound Structure
% Inhibition
cPLA2 iPLA2 sPLA2
16a 46.9 91.1 43.4
16c 57.5 89.1 44.8
16d 70.5 77.1 54.4
17a 11.2 - -
17c 43.1 - -
23a 82.3 76.0 57.5
23b 85.5 88.4 63.9
24a 72
XI(50)
0.011
59
25a 52
XI(50)
0.017
81
Table 1. In vitro results of the human phospholipases A2 inhibition  by 2-oxoamides.
22-24 Ar 
Yield (%) 
d e f 
a Phenyl 53 95 98 
b Naphthyl 69 84 97 
 
a Data taken from Ref. 4
